Genome of the Bacterium Streptococcus pneumoniae Strain R6 (original) (raw)

J Bacteriol. 2001 Oct; 183(19): 5709–5717.

JoAnn Hoskins,1 William E. Alborn, Jr.,1 Jeffrey Arnold,2 Larry C. Blaszczak,1 Stanley Burgett,2 Bradley S. DeHoff,2 Shawn T. Estrem,1 Lori Fritz,2 Dong-Jing Fu,2 Wendy Fuller,2 Chad Geringer,2 Raymond Gilmour,1 Jennifer S. Glass,1 Hamid Khoja,1 Angelika R. Kraft,1 Robert E. Lagace,3 Donald J. LeBlanc,1 Linda N. Lee,1 Elliot J. Lefkowitz,4 Jin Lu,1 Patti Matsushima,1 Scott M. McAhren,2 Margaret McHenney,2 Kevin McLeaster,2 Christopher W. Mundy,2 Thalia I. Nicas,1 Franklin H. Norris,2 MaryJeanne O'Gara,1 Robert B. Peery,1 Gregory T. Robertson,1 Pamela Rockey,2 Pei-Ming Sun,1 Malcolm E. Winkler,1 Yong Yang,1 Michelle Young-Bellido,1 Genshi Zhao,1 Christopher A. Zook,1 Richard H. Baltz,1 S. Richard Jaskunas,1 Paul R. Rosteck, Jr.,2 Paul L. Skatrud,1 and John I. Glass1,*

JoAnn Hoskins

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

William E. Alborn, Jr.

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Jeffrey Arnold

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Larry C. Blaszczak

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Stanley Burgett

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Bradley S. DeHoff

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Shawn T. Estrem

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Lori Fritz

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Dong-Jing Fu

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Wendy Fuller

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Chad Geringer

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Raymond Gilmour

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Jennifer S. Glass

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Hamid Khoja

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Angelika R. Kraft

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Robert E. Lagace

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Donald J. LeBlanc

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Linda N. Lee

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Elliot J. Lefkowitz

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Jin Lu

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Patti Matsushima

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Scott M. McAhren

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Margaret McHenney

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Kevin McLeaster

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Christopher W. Mundy

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Thalia I. Nicas

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Franklin H. Norris

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

MaryJeanne O'Gara

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Robert B. Peery

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Gregory T. Robertson

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Pamela Rockey

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Pei-Ming Sun

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Malcolm E. Winkler

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Yong Yang

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Michelle Young-Bellido

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Genshi Zhao

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Christopher A. Zook

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Richard H. Baltz

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

S. Richard Jaskunas

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Paul R. Rosteck, Jr.

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Paul L. Skatrud

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

John I. Glass

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

Infectious Diseases Research and Clinical Investigation1 and Biological Research Technologies and Proteins,2 Eli Lilly and Company, Indianapolis, Indiana 46285; Incyte Genomics, Palo Alto, California, 943043; and Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352944

*Corresponding author. Mailing address: Infectious Diseases Research, Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN 46285-0438. Phone: (317) 277-0143. Fax: (317) 276-1743. E-mail: moc.yllil@i_nhoj_ssalg.

Received 2001 Jun 20; Accepted 2001 Jul 13.

Copyright © 2001, American Society for Microbiology

Abstract

Streptococcus pneumoniae is among the most significant causes of bacterial disease in humans. Here we report the 2,038,615-bp genomic sequence of the gram-positive bacterium S. pneumoniae R6. Because the R6 strain is avirulent and, more importantly, because it is readily transformed with DNA from homologous species and many heterologous species, it is the principal platform for investigation of the biology of this important pathogen. It is also used as a primary vehicle for genomics-based development of antibiotics for gram-positive bacteria. In our analysis of the genome, we identified a large number of new uncharacterized genes predicted to encode proteins that either reside on the surface of the cell or are secreted. Among those proteins there may be new targets for vaccine and antibiotic development.

Worldwide, approximately 1.1 million deaths annually are attributed to Streptococcus pneumoniae infection (22), accounting for 9% of all deaths in underdeveloped countries (37). S. pneumoniae disease is not limited to the developing world. Despite the availability of a broad arsenal of antibiotics and a vaccine, S. pneumoniae remains one of the top 10 causes of death in the United States (22). Furthermore, nearly one-third of the S. pneumoniae isolates obtained from patients in the United States are resistant to penicillin (11, 45) and the incidence of strains resistant to multiple antibiotics is increasing, making infections caused by this organism more difficult to treat.

S. pneumoniae is a gram-positive coccus and a member of the lactic acid bacteria, so named for their primary metabolic byproduct. The lactic acid bacteria include the lactococci, a group important in food and dairy industries, and the genera Enterococcus and Streptococcus. Bacteria belonging to the genus Streptococcus live in association with animal hosts, as either pathogenic or commensal organisms. Human pathogens include the beta-hemolytic species, such as Streptococcus pyogenes (Lancefield group A) and Streptococcus agalactiae (group B), as well as the human cariogenic species Streptococcus mutans. A number of commensal species of streptococci can occasionally cause opportunistic infections. S. pneumoniae (also known as pneumococcus or Diplococcus pneumoniae) is the major cause of acute bacterial pneumonia and otitis media. S. pneumoniae is also a transient commensal, colonizing the throat and upper respiratory tract of 40% of humans_. S. pneumoniae_ isolates vary in their polysaccharide capsule, and at least 90 different capsule types have been identified. Specific capsule types are associated with the capacity to cause severe disease.

To aid the search for new therapies, we determined the entire genomic DNA sequence of S. pneumoniae strain R6. S. pneumoniae R6 is a descendant of the type 2 capsule S (smooth or encapsulated) clinical isolate used by Avery and coworkers to demonstrate the genetic function of DNA (2), and it is used worldwide as a standard laboratory strain. The lack of a polysaccharide capsule in R6 renders it avirulent and a safe strain with which to work. The essential utility of the strain is its genetic malleability.

MATERIALS AND METHODS

Bacterial strain.

The S. pneumoniae R6 isolate was obtained from Alexander Tomasz (Rockefeller Institute, New York, N.Y.). The strain is hex+, not a hex mutant as had been reported previously (3). The parental S. pneumoniae strain for R6 is R36A, which is a nonencapsulated strain derived from the capsular type 2 clinical isolate strain D39. R36A has multiple interruptions in the type 2 capsular locus inherited from D39 (21). Rollin Hotchkiss assayed single R36A colonies for competence in transformation_. S. pneumoniae_ R6 was selected based on a high capacity to be transformed to penicillin resistant by using DNA from a laboratory-constructed isolate of penicillin-resistant S. pneumoniae. The sequenced isolate of S. pneumoniae R6 is available from the American Type Culture Collection (ATCC BAA-255).

Genome sequencing.

Genomic DNA was isolated from bacteria grown in brain heart infusion medium (Becton Dickinson, Franklin Lakes, N.J.). The purification process included multiple phenol extractions, ethanol precipitations, and spoolings. DNA was sheared, size fractionated, and used to create plasmid and fosmid libraries. Clones from those libraries were end sequenced using both dye-primer and dye-terminator DNA sequencing methods. In the random shotgun phase of the project, ≈44,000 sequences were obtained. Gaps were closed either by sequencing spanning PCR products or by directly sequencing from the ends of contigs using custom primers and genomic DNA as a template (18). DNA sequences were analyzed and assembled using PHRED, PHRAP, and CONSED (http://www.phrap.org/) (13, 17). Insertion sequences and rRNA operons present in multiple copies created sequence assembly problems because no single DNA sequence covered the entire repetitive element. We developed a high-scoring-pairs algorithm to correctly assemble contigs flanked by these large repetitive elements (unpublished data). The sequence assembly was confirmed by a combination of Southern blotting, PCR, and comparison of the electrophoretically measured insert sizes to map locations of the end sequences from fosmid and plasmid inserts.

One open reading frame (ORF), encoding a hypothetical surface protein (spr0075), was predicted by this assembly to contain five copies of a 456-bp nearly perfect repeat. Southern blot analysis of this region of the genome suggested that there were seven copies of this repeat present within this gene (data not shown). We predicted that this gene should be approximately 912 bp larger than indicated; however, the reported sequence for the complete genome did not include the additional predicted but unsequenced 912 bp.

Sequence analysis and annotation.

Annotation of the S. pneumoniae genome was performed by utilizing a combination of programs for gene prediction, similarity searching, and functional assignment. The information from these analyses was imported into a relational database based upon Microsoft SQL Server. The user interface for this database was a series of web pages that accessed the SQL Server database and allowed us to query available analysis data. Additional pages allowed us to directly hand-annotate the individual gene records, thus allowing us to refine start sites and add functional descriptions and notes. This web-based client interface was developed using Microsoft Active Server Pages technology to directly query and update the database records. Basic sequence analysis tools were provided by the Genetics Computer Group (GCG) package of programs (Wisconsin Package version 10.0; GCG, Madison, Wis.).

ORF identification.

Determination of potential protein-encoding sequences utilized Glimmer (http://www.tigr.org/softlab/glimmer/glimmer.html) (9) to create organism-specific ORF models that could then be used to search the entire genome for ORFs matching the predictive models. The genome was first arranged such that the initial base of the ATG start codon of the putatively identified dnaA gene was base number 1 of the forward strand. Each predicted ORF was then assigned an S. pneumoniae identification number. ORF spr0001 was assigned to the putative dnaA gene, and each subsequent ORF was then numbered consecutively according to its left-most base (the start codon for ORFs on the forward strand, and the stop codon for genes on the reverse strand).

Gene assignments.

BLAST searches were performed on all predicted ORFs using a blastp search of amino acid similarities to sequences in the GenBank nonredundant protein database. The BLAST data were parsed using the blast modules of the BioPerl tool kit (http://www.bioperl.org) and then imported into SQL server tables for analysis. In addition to BLAST similarity searching, we also tentatively identified functional domains within the S. pneumoniae ORFs by searching for similarities to the Prosite motif library (20) and the Blocks database of protein families (19). Programs from the GCG package provided composition and hydrophobicity analyses along with scanning for potential signal peptide domains. The results of these additional analyses allowed us to refine the gene assignments initially made with BLAST. Furthermore, alignments with known proteins provided assistance with start-codon prediction.

The results of all of these searches were used to provide putative identification of each S. pneumoniae ORF when a significant hit between an S. pneumoniae sequence and GenBank sequence was found. A combination of computer-aided gene prediction along with human inspection of each gene record was then used to finalize gene assignments for each S. pneumoniae ORF.

RNA identification.

To identify genomic sequences that code for tRNAs, the set of programs that encompass the software package tRNAscan-SE (24) was used. rRNAs were identified by their similarity to the corresponding genes in the Ribosome Database Project sequence database (25). The sequences for tmRNA (51), the 4.5S signal recognition particle (53), and RNase P (28) were also identified based upon sequence similarities with known representatives of these RNA genes.

Nucleotide sequence accession number.

The genomic sequence was assigned accession number AE007317 in the GenBank data base. The annotated genome and supplementary data are available on the World Wide Web at http://www.lilly.com/s.pneumoniae.

RESULTS AND DISCUSSION

The S. pneumoniae single circular chromosome of 2,038,615 bp (40% G+C content) contains 2,043 predicted protein coding regions and 73 noncoding RNA genes, which include four rRNA operons. The genomic origin of replication has not been experimentally identified in S. pneumoniae; however, based on the presence of clusters of DnaA boxes and other genomic features, we hypothesize that the S. pneumoniae origin of DNA replication is upstream of dnaA, which is gene spr0001 in our nomenclature system (16).

As anticipated from the work of Iannelli and colleagues (21), relative to strain D39, the encapsulated strain from which R6 was ultimately derived, we noted a 7,504-bp deletion within the ≈18-kbp region that encodes the capsule biosynthesis genes. This deletion results in the absence of seven complete genes as well as the 3′ end of _cps_2A and the 5′ end of _cps_2H.

Other than genes associated with capsule synthesis, the genes encoding several putative virulence functions are present in the R6 genome (Table ​1). These include the genes for previously described S. pneumoniae surface proteins, secreted proteins and bacteriocins, and all previously reported two-component response regulator systems (13 potential histidine protein kinases and response regulator pairs plus an unpaired 14th response regulator) (46).

TABLE 1

Genes found in R6-encoded proteins that have been studied for a role in S. pneumoniae virulence or as protective antigens to S. pneumoniaea

Gene no. Gene name Description
spr0121 pspA Surface protein (choline binding), functions in inhibition of complement activation and may involve lactoferrin binding (30, 48)
spr0286 hysA Hyaluronidase (30)
spr0674 sodA Manganese cofactored superoxide dismutase (30)
spr0867 lytB Endo-beta-_N_-acetylglucosaminidase (15)
spr0884 ppmA Surface-located proteinase maturation protein (33)
spr1042 iga Immunoglobulin A1 protease (49)
spr1323 nox (nadH) NADH oxidase (1)
spr1492, spr1493 psaB, psaC With psaA, part of manganese ABC transporter operon (30)
spr1494 psaA Adhesin, manganese ABC transporter substrate-binding protein (30)
spr1536, spr1531 nanA, nanB Neuraminidase, sialidase (30)
spr1707 amiA Oligopeptide ABC transporter substrate-binding protein (33)
spr1739 ply (tacY) Pneumolysin (thiol-activated cytolysin) (30)
spr1754 lytA Autolysin (_N_-acetylmuramoyl-l-alanine amidase) (30)
spr1995 cbpA (pcpA) Surface protein (choline binding), functions in adherence and immunoglobulin A inactivation (30)
spr0040b thmA Bacteriocin-like amphipathic pore-forming peptide precursor (26)
spr0059b bgaC Beta-galactosidase 3 (52)
spr0351,b spr0337b pcpC, cbpF (pcpC1) Surface protein (choline binding), unknown function
spr0462b blpS (iR1) Regulator of bacteriocin production (39)
spr0465b iP Bacteriocin-like peptide, regulator (39)

Drug resistance via efflux pumps is an important contributor to virulence in Staphylococcus aureus and other gram-positive pathogens. Although S. pneumoniae contains 14 genes that are possible antibiotic efflux pumps (Table ​2), these efflux pump genes may not be significant contributors to S. pneumoniae virulence. Antibiotic extrusion is not as common a source of resistance in S. pneumoniae as it is in S. aureus (e.g., quinolones). S. pneumoniae is not intrinsically resistant to most classes of agents, and among the exceptions (e.g., aminoglycosides and quinolones) resistance is not the result of drug efflux pumps.

TABLE 2

Possible/probable drug efflux pumps encoded by S. pneumoniae R6

Gene no. Gene namea Description
spr0137 ABC-NBD&MSP This is similar to the E. coli msbA gene, which is proposed by Milton Saier, Jr., and Ian Paulsen to function in drug efflux (http://www.biology.ucsd.edu/∼ipaulsen/transport/)
spr0144 Conserved hypothetical Possible macrolide efflux permease of the major facilitator superfamily
spr0610 ABC-NBD/truncation Probably part of a drug resistance ABC transporter pump
spr0875 pmrA Major facilitator superfamily multidrug resistance efflux pump
spr0880 tehB Multidrug resistance; K+-tellurite ethidium and proflavin transport (there is no tehA gene in S. pneumoniae R6)
spr0971 mefE ABC transporter membrane-spanning permease for macrolide efflux
spr1023 ABC-MSP Possible macrolide efflux pump
spr1052 MATE Hypothetical multi-antimicrobial extrusion (MATE) family transporter
spr1183 ABC-NBD/truncation Possible multidrug efflux pump, clyB/comA paralog, missing NH2 half
spr1203 ABC-NBD&MSP Hypothetical ABC transporter possibly involved in multidrug resistance or toxin secretion
spr1352 bta Bacterocin transport accessory protein
spr1378–81 ABC-MSP/truncation This is a fragmented ABC transporter gene similar to the S. aureus pepT efflux pump
spr1734–6 ABC-NBD/truncation This is a fragmented ABC transporter gene similar to the Mycobacterium tuberculosis MTb1273 efflux pump
spr1877 MATE Hypothetical multi-antimicrobial extrusion (MATE) family transporter

Surface proteins.

Surface proteins are of special interest because of their potential role in virulence and their possible utility in vaccine development and also because of their potential accessibility to antimicrobial agents. The R6 genome includes single copies of the previously described virulence-associated genes, including four that encode proteins that are under study as vaccine candidates (PspA, PsaA, CbpA, and pneumolysin) (5).

Based on sequence analyses, we predict that a large number of proteins either reside on the S. pneumoniae cell surface or are secreted from the cell. These proteins include 471 with predicted signal peptide sequences, 109 possessing lipoprotein lipid attachment sites, and 10 that are recognized by choline-binding domains, an unusual means of surface attachment found in S. pneumoniae (Fig. ​1). We could predict no function for ≈23% of these potential surface-located or secreted proteins, which likely play roles in pneumococcal cell surface biology.

An external file that holds a picture, illustration, etc. Object name is jb1910759001.jpg

S. pneumoniae substrate transport, carbohydrate and glutamine metabolism, and selected categories of cell surface proteins. Transporters are shown in the cell on the right and are grouped by substrate specificity: multidrug and peptide exporters (red), carbohydrates (yellow), cations (blue), anions and amino acids (green), nucleosides, purines, and pyrimidines (purple), and other substrates (white). Question marks indicate uncertainty in the identity of the genes, direction of transport, or substrate. Permeases are drawn as rectangles; porins are drawn as cylinders; ATPases are drawn as ovals overlapping rectangles; other transporters are drawn as ovals; and ABC transporter elements are depicted as circles for nucleotide-binding proteins, diamonds for membrane-spanning permeases, and rectangles for the substrate-binding proteins. The 21 hypothetical ABC transporters for which no substrate could be predicted are not shown in the figure. Glutaminase, an enzyme we expected to find but could not identify, is listed in green italics. The glycolytic pathway leading to lactate is shown along with the pathway for glutamine to nitrogen-containing compounds. (Additional material on carbohydrate metabolism is at http://www.lilly.com/s.pneumoniae.) The ATP consumption and production values listed are for monosaccharides; ATP values for disaccharide catabolism are in parentheses. The choline-binding proteins are autolysin (LytA), endo-beta-_N_-acetylglucosaminidase (LytB), a surface protein involved in adherence and immunoglobulin A inactivation (CbpA), a putative lactoferrin-binding protein (PspA), and several surface proteins of unknown function (CbpD, PcpA, PcpC, PcpC1). Micrograph reprinted from reference 47 with permission of the publisher.

In S. aureus, a transpeptidase called sortase anchors exported proteins containing an LPXTG motif followed by a C-terminal hydrophobic domain and a charged tail to the cell wall peptidoglycan (29, 41). Although sortases are predicted to be present in all gram-positive bacteria, previously no sortase ortholog had been identified in S. pneumoniae, nor could we identify one using BLAST searches. Using a Smith and Waterman algorithm (43), we determined that a single S. pneumoniae R6 gene, spr1098, likely coded for a sortase. Furthermore, we identified 13 genes that coded for proteins containing the LPXTG motif and other sortase substrate features. Six of these proteins are known to be present on the cell surface, while seven are novel and currently categorized as hypothetical with no known function (Fig. ​1). Our observations about sortase in strain R6 conflict with a report by Pallen and colleagues, who identified four sortase-like protein genes and “many” potential sortase substrates in the genome of a virulent S. pneumoniae strain with a type 4 capsule (34).

Lipoteichoic acid (LTA) is another cell surface component that contributes to the bacterium's interaction with the human host. Biochemical studies have not detected the presence of d-alanine, a key component of LTA in many organisms, in S. pneumoniae LTA (14). In conflict with the apparent absence of d-alanine in S. pneumoniae LTA, we found an apparently complete _dlt_ABCD operon that is homologous to those responsible for the addition of d-alanine to LTA in Bacillus subtilis and in Lactobacillus casei. Previously we suggested that this operon may be silent or defective or that these genes may be active under specific physiological conditions (3). Gene expression studies (data not shown) revealed expression of mRNA from each of these genes under normal laboratory growth conditions. The precise role of the _dlt_ABCD operon in the biology of S. pneumoniae remains unknown, although inactivation of this operon in S. mutans confers increased acid sensitivity (4).

Competence.

S. pneumoniae competence, i.e., its natural capacity to take up DNA, has been studied in detail and a number of competence-specific operons have been identified (23). S. pneumoniae R6 contains all of the genes induced during competence as noted by Lee and Morrison (23), including two identical copies of comX (each adjacent to a ribosomal operon). Additional genes reported to be induced during competence, but whose role in this process remains unknown, are also present (36, 40). These 49 putative competence genes are grouped in 30 apparent operons and are found mostly on the leading strands extending away from the putative origin of replication (as are ≈80% of all S. pneumoniae genes).

As might be predicted as a consequence of the capacity of S. pneumoniae to take up DNA, its genome is littered with genes that are apparently derived from other bacteria. Horizontal gene transfer is clearest for those genes that have been found only in gram-negative bacterial genomes. There are 40 ORFs that are similar to genes in gram-negative bacteria and that have not been found in other gram-positive genome sequences. This is not surprising, because S. pneumoniae occupies the same niche in the human respiratory system as several gram-negative species. Additionally, at least 2% of S. pneumoniae genes are significantly truncated relative to orthologous genes characterized in other bacteria (Table ​3). Many of the deletions are at the 5′ ends of the ORFs, which suggests that the ORFs may be nonfunctional remnants of their parental genes. This incidence may also be a consequence of competence. Coding regions may be missing from these genes because only part of the ORFs were acquired during the assimilation of foreign DNA, or because the genes were not essential to the pneumococcus and mutations are of no consequence. Transporters are the most frequently truncated genes. Among that set are five ORFs that are similar to genes encoding drug efflux pumps.

TABLE 3

Truncated and/or fragmented genes in S. pneumoniae R6

Gene no. Gene namea Description
spr0105 ABC-NBP&MSP-truncation ABC transporter similar to comA
spr0106 ABC-NBP&MSP-truncation ABC transporter similar to comA
spr0223 ABC-SBP-truncation ABC transporter substrate-binding protein (iron transport)
spr0224 ABC-SBP-truncation ABC transporter substrate-binding protein (iron transport)
spr0299 Conserved hypothetical
spr0300 Conserved hypothetical
spr0324 Transposase G-truncation Uncharacterized transposase
spr0346 _alkD_-truncation DNA alkylation repair enzyme
spr0347 _alkD_-truncation DNA alkylation repair enzyme
spr0349 _cbpG_-truncation Choline-binding protein G
spr0466 Conserved hypothetical
spr0467 Conserved hypothetical
spr0468 Conserved hypothetical
spr0469 Conserved hypothetical
spr0523 Transposase H-truncation Uncharacterized transposase
spr0535 _glnQ_-truncation ABC transporter ATP-binding protein (glutamine)
spr0536 _glnQ_-truncation ABC transporter ATP-binding protein (glutamine)
spr0610 ABC-NBD-truncation ABC transporter ATP-binding protein (unknown substrate)
spr0620 ABC-SBP-truncation ABC transporter substrate-binding protein (unknown substrate)
spr0621 ABC-SBP-truncation ABC transporter substrate-binding protein (unknown substrate)
spr0646 _bgl_-truncation Phospho-beta-gluco or galactosidase
spr0737 Conserved hypothetical
spr0852 _ald_-truncation Alanine dehydrogenase
spr0853 _ald_-truncation Alanine dehydrogenase
spr0854 _ald_-truncation Alanine dehydrogenase
spr0910 _phtE_-truncation Pneumococcal histidine triad protein E precursor
spr0957 Relaxase-truncation Tn_5252_, relaxase
spr0958 Relaxase-truncation Tn_5252_, relaxase
spr1033 _serB_-truncation Phosphoserine phosphatase
spr1077 _lacX_-truncation Function unknown
spr1095 _metY_-truncation _O_-Acetylhomoserine sulfhydrylase
spr1096 _metY_-truncation _O_-Acetylhomoserine sulfhydrylase
spr1133 _leuD_-truncation 3-Isopropylmalate dehydratase small subunit
spr1183 ABC-NBD-truncation ABC transporter ATP-binding protein (possibly multidrug efflux)
spr1186 _npl_-truncation _N_-Acetylneuraminate lyase subunit
spr1187 _npl_-truncation _N_-Acetylneuraminate lyase subunit
spr1285 _spnIR_-truncation Type II restriction endonuclease, uncharacterized
spr1286 _spnIR_-truncation Type II restriction endonuclease, uncharacterized
spr1378 ABC-MSP-truncation
spr1379 ABC-MSP-truncation
spr1380 ABC-MSP-truncation
spr1381 ABC-MSP-truncation
spr1520 _npl_-truncation _N_-Acetylneuraminate lyase subunit
spr1521 _npl_-truncation _N_-Acetylneuraminate lyase subunit
spr1683 _galE_-truncation UDP-galactose 4-epimerase
spr1734 ABC-NBD-truncation ABC transporter ATP-binding protein (unknown substrate)
spr1736 ABC-NBD-truncation ABC transporter ATP-binding protein (unknown substrate)
spr1772 Conserved hypothetical
spr1871 _pcp_-truncation Pyrrolidone carboxyl peptidase
spr1872 _pcp_-truncation Pyrrolidone carboxyl peptidase
spr1900 Conserved hypothetical
spr1955 _arcA_-truncation Arginine deiminase
spr1956 _arcA_-truncation Arginine deiminase
spr1984 Transposase H Uncharacterized transposase
spr1985 Transposase H Uncharacterized transposase
spr1989 _glpD_-truncation Glycerol 3-phosphate dehydrogenase
spr1990 _glpD_-truncation Glycerol 3-phosphate dehydrogenase
spr1999 _clpC_-truncation Class III stress response-related ATPase
spr2000 _clpC_-truncation Class III stress response-related ATPase
spr2036 Conserved hypothetical
spr2037 Conserved hypothetical
spr2038 Conserved hypothetical
spr2039 Conserved hypothetical

Comparative genomics and metabolism.

In most respects, the S. pneumoniae gene complement is very similar to that of the prototypic gram-positive bacterium B. subtilis. More than 53% of the S. pneumoniae genes have highly similar counterparts in the B. subtilis genome (Fig. ​2). Systems for cell division, DNA replication and repair, translation, cell wall biosynthesis, and some central catabolic and biosynthetic pathways are basically the same as in B. subtilis. Major cellular systems and features that are notably different include energy metabolism, transport, amino acid biosynthesis, transcription termination, intracellular proteases, and the presence of three large sets of _S. pneumoniae_-specific repetitive elements in the genome.

An external file that holds a picture, illustration, etc. Object name is jb1910759002.jpg

Comparison of the predicted S. pneumoniae R6 ORFs with those of other completely sequenced genomes. All S. pneumoniae R6 ORFs were searched against other genomes with BLAST2. The percentage of S. pneumoniae R6 ORFs with significant similarity (E ≤ 10−12) to predicted ORFs in the other genomes is shown.

As is characteristic of the lactic acid bacteria, S. pneumoniae is a nutritionally fastidious facultative anaerobe requiring a complex medium for growth. This bacterium obtains energy strictly via fermentation and is incapable of respiratory metabolism, either aerobically or anaerobically, as is true of all streptococcal species (38). The only nutrients from which the streptococci can obtain sufficient energy to support growth and cell division are carbohydrates, which are oxidized to pyruvate via glycolysis (with the exception of a few species that can ferment arginine). We identified a large set of genes that encode enzymes necessary for transport of at least 12 different carbohydrates into the cell and for their subsequent conversion to an intermediate in glycolysis.

S. pneumoniae R6, as expected, encodes all genes necessary for the oxidation of carbohydrates to pyruvate via glycolysis and would be expected to reoxidize most, if not all, of the NADH produced by the reduction of pyruvic acid to lactic acid. R6 contains genes for the synthesis of phosphotransacetylase, acetokinase, and NADH oxidase, which would allow it to convert pyruvate to acetate with concomitant production of an additional ATP, and the reoxidation of NADH (38). Although fermentation is the least energy efficient of oxidative processes, S. pneumoniae did not maximize this energy production by exclusively using the phosphoenolpyruvate-dependent phosphotransferase system to import carbohydrates. Five sugar species are imported by using energetically less-efficient ABC transporters. We found no genes that might encode cation antiporters of sugars, although we identified several amino acid/cation symport systems (Fig. ​1). All genes necessary for synthesis of the major ATPase of lactic acid bacteria, the F0F1-ATPase, are present. This proton pump works at the expense of ATP, but it can also serve as an ATP synthase, as well as serving as the major regulator of intracellular pH among lactic acid bacteria. We did not find the genes required for a complete electron transport chain that might be associated with either aerobic or anaerobic respiration.

No lactic acid bacterial species encodes a complete tricarboxylic acid (TCA) cycle, and the S. pneumoniae R6 genome contains none of the 18 genes comprising this aerobic oxidative pathway. In other organisms, including those without complete TCA cycles, some of the TCA enzymes also have roles in the synthesis of certain amino acid precursors. As a result, S. pneumoniae R6 is incapable of synthesizing aspartate (and hence lysine, methionine, threonine, and isoleucine) from oxaloacetate, nor can it synthesize glutamate (and hence arginine) via α-ketoglutarate. A defined medium developed specifically for S. pneumoniae contains those amino acids, so the incomplete biosynthetic pathways were expected. We were unable to identify complete pathways for the synthesis of glycine, histidine, and leucine, all of which are included in the S. pneumoniae defined medium. Valine is also included in the S. pneumoniae defined medium, so identification of an apparently complete pathway for valine biosynthesis was unexpected (42).

The presence in S. pneumoniae of an ortholog to the Cercospora nicotianae pdx1 gene suggests S. pneumoniae may have a pyridoxal biosynthetic pathway (12). The biosynthesis pathways for other required cofactors (biotin, choline, pantothenate) are either incomplete or absent. Presence of partial pathways for the synthesis of many of these amino acids and cofactors in S. pneumoniae is not surprising. In many cases these enzymes make possible the conversion of molecules imported into the cell into other necessary metabolic components. Glutamine is an example of this type of metabolic conversion. Although S. pneumoniae cannot make the starting material for glutamate, α-ketoglutarate, it does encode the enzymes needed to utilize glutamine as a nitrogen source. In S. mutans, glutamine has been shown to be a principal source of nitrogen (8). There are 22 genes encoding the elements of 7 different ABC transporters predicted to transport glutamine. That represents 10% of the transport genes in S. pneumoniae. The allocation of the S. pneumoniae genome capacity to glutamine transport suggests that glutamine is also needed for more than its role as a component of proteins.

Hydrogen peroxide is produced by S. pneumoniae through the action of pyruvate oxidase (SpxB) under conditions of aerobic growth. This may be a mechanism by which the pneumococcus inhibits the growth of other common pathogens of the human upper respiratory tract such as Haemophilus influenzae, Moraxella catarrhalis, and Neisseria meningitidis, which are infrequently cocultured with S. pneumoniae from patient samples (35). Unlike those gram-negative species, S. pneumoniae has the capacity to resist oxidative stress caused by H2O2. In Escherichia coli, oxidative stress induces the expression of a set of ≈30 proteins under the transcriptional control of OxyR (6). Based on their similarity to OxyR, either spr0593 or spr0828, which are bacterial regulatory proteins of the LysR family, might possibly regulate the S. pneumoniae enzymes synthesized in response to H2O2. These include superoxide dismutase, glutathione reductase, glutaredoxin, DNA-binding stress protein, and two thioredoxin reductases. Although there are also genes for several peroxidases that can be used to ameliorate oxidative stress, S. pneumoniae does not encode catalase.

Bacterial energy-dependent intracellular proteases perform a variety of tasks, possibly including that of the proteasome, which degrades aberrant and nonfunctional proteins in eukaryotes and archaea (10). S. pneumoniae R6 possesses single copies of the genes encoding the ClpP and FtsH proteases, but it is notably deficient of the genes encoding HslV and the ubiquitous Lon protease. While some bacteria with relatively large genomes, such as E. coli and B. subtilis, encode all four of these energy-dependent proteases, most eubacteria encode only a subset (10). The S. pneumoniae energy-dependent protease gene set appears to be characteristic of the gram-positive genera Enterococcus, Streptococcus, and Staphylococcus, but not of the mycoplasmas.

Repetitive elements.

DNA sequences from three classes of repetitive elements, BOX, RUP, and IS, comprise >3% of the S. pneumoniae genome. These kinds of repetitive elements make up more of the S. pneumoniae genome than of any other bacterial genome sequenced to date. Functions for some of these sequences are controversial. The BOX elements are predicted to form stable secondary structures that may serve as the binding site for a protein responsible for modulating the expression of downstream genes (27). Insertion of heterologous DNA into the BOX element upstream of the comA gene produces S. pneumoniae incapable of competence (27). Additionally, Weiser showed that insertion of a BOX element upstream of a locus apparently involved in phase variation increases expression of downstream genes encoding the opacity phenotype (50). The 107-bp RUP elements, predicted to form stable secondary structures, are proposed to be active insertion elements transactivated by the transposase of IS_630_-Spn_1_ (32).

Almost all BOX and RUP elements are entirely in intergenic spaces. We hypothesized that analysis of the locations of the BOX and RUP elements relative to the transcriptional orientation of the genes surrounding them might offer clues about their potential regulatory roles. In S. pneumoniae between adjacent genes in the same transcriptional orientation, the boundaries of transcriptional units are often unclear; accordingly, promoters and transcription termination signals are difficult to identify. Between pairs of adjacent genes oriented 5′ end to 5′ end on opposite strands of the chromosome, or at least in the vicinity of those genes, there are likely to be pairs of transcriptional promoters. Likewise, there must be a transcription termination signal or signals between pairs of adjacent genes oriented 3′ end to 3′ end on opposite strands of the chromosome (factor-independent transcription termination signals have been identified in streptococci that can function bidirectionally [44]). Almost 3 times as many BOX elements and 1.5-fold more RUP elements are located between the genes oriented 3′ to 3′ than between genes oriented 5′ to 5′, and the insertion of IS elements flanking some of these elements may artificially deflate those ratios (Table ​4). This suggests a role for the RUP and BOX elements in transcription termination. Another possible function is suggested by the fact that secondary structures that RUP and BOX elements would assume at the 3′ ends of mRNAs are more complex than those observed for other factor-independent transcription termination signals (27, 32), and S. pneumoniae does not encode rho factor. These elements might enhance gene expression by either stabilizing mRNAs or serving as binding sites for regulatory proteins.

TABLE 4

Transcriptional orientations of genes flanking BOX and RUP repetitive elements

Element No. (%) of elementsa
→BOX or RUP→ →BOX or RUP← ←BOX or RUP→
BOX 80 (4) 26 (13) 9 (4)b
RUP 49 (3) 21 (11) 14 (7)b

Previous analyses indicate numerous IS elements were present in the DNA of various strains of S. pneumoniae. The genome of R6 contains at least 60 complete or partial copies of 10 different IS elements, representing the families IS_L3_, IS_5_, IS_630_, IS_3_, IS_30_, and IS_605_. We identified three novel IS elements. We did not find an IS_1202_, which was previously identified in a progenitor of the R6 strain, S. pneumoniae D39 (31). Most of the copies of the IS elements appear to be only remnants, as only seven possess the expected full-length sequences of putative transposase genes. The remaining copies all contain frameshifts, stop codons, or both within the ORF, and many have substantial amino acid substitutions, suggesting that they are no longer active. It is possible that these inactive insertion elements still play an important role in the evolution of this genome. For example, they may provide regions of homology that are sites for homologous recombination in the acquisition of genes from related organisms carrying these same insertion sequences but different flanking genes (7).

The capacity to identify all potential genes within this pathogen should greatly facilitate the identification of novel targets for antibiotic discovery as well as new candidates for vaccine development. This process will be significantly enhanced by the comparison of the S. pneumoniae R6 sequence to that of pathogenic strains of S. pneumoniae (www.tigr.org and http: //genome.microbio.uab.edu/strep/). These comparisons, in concert with genetic and gene expression studies, should catalyze expansion of S. pneumoniae biology.

ACKNOWLEDGMENTS

We thank Amy Hahn, Travis Bennett, Lara Braverman, Joanne Dyer, Bruce Glover, Ken Holstein, Dennis Howell, Ivan Jenkins, Tammy Jones, Rebecca Leonard, Melud Nabavi, Regine Porter, Patricia Solenberg, and Angie Wu for their technical assistance, Ron Swanson for advice on the sequencing project, and Janet Yother and Dalai Yan for their advice on the manuscript.

Principal authors JoAnn Hoskins and John Glass contributed equally to this project.

This work was supported by Eli Lilly and Company and the Incyte Genomics, Inc. Pathoseq database program.

REFERENCES

1. Auzat I, Capuy-Regaud S, LeBras G, DosSantos D, Ogunniyi A D, LeThonas I, Garel J-R, Paton G C, Tombe M C. The NADH oxidase of Streptococcus pneumoniae: its involvement in competence and virulence. Mol Microbiol. 1999;34:1018–1028. [PubMed] [Google Scholar]

2. Avery O T, MacLeod C, McCarty M. Studies on the chemical nature of the substance inducing transformation of the pneumococcal types. J Exp Med. 1944;79:137–158. [PMC free article] [PubMed] [Google Scholar]

3. Baltz R H, Norris F H, Matsushima P, DeHoff B S, Rockey P, Porter G, Burgett S, Peery R, Hoskins J, Braverman L, Jenkins I, Solenberg P, Young M, McHenney M A, Skatrud P L, Rosteck P R., Jr DNA sequence sampling of the Streptococcus pneumoniae genome to identify novel targets for antibiotic development. Microb Drug Resist. 1998;4:1–9. [PubMed] [Google Scholar]

4. Boyd D A, Cvitikovitch D G, Bleiweis A S, Kiriukhin M Y, Debabov D V, Neuhaus F C, Hamilton I R. Defects in d-alanyl-lipoteichoic acid synthesis in Streptococcus mutans results in acid sensitivity. J Bacteriol. 2000;182:6055–6065. [PMC free article] [PubMed] [Google Scholar]

5. Briles D E, Hollingshead S, Brooks-Walter A, Nabors G S, Ferguson L, Schilling M, Gravenstein S, Braun P, King J, Swift A. The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine. 2000;18:1707–1711. [PubMed] [Google Scholar]

6. Christman M F, Storz G, Ames B N. OxyR, a positive regulator of hydrogen peroxide-inducible genes in Escherichia coli and Salmonella typhimurium, is homologous to a family of bacterial regulatory proteins. Proc Natl Acad Sci USA. 1989;86:3484–3488. [PMC free article] [PubMed] [Google Scholar]

7. Claverys J P, Prudhomme M, Mortier-Barriere I, Martin B. Adaptation to the environment: Streptococcus pneumoniae, a paradigm for recombination-mediated genetic plasticity? Mol Microbiol. 2000;35:251–259. [PubMed] [Google Scholar]

8. Dashper S G, Riley P F, Reynolds E C. Characterization of glutamine transport in Streptococcus mutans. Oral Microbiol Immunol. 1995;10:183–187. [PubMed] [Google Scholar]

9. Delcher A L, Harmon D, Kasif S, White O, Salzberg S L. Improved microbial gene identification with GLIMMER. Nucleic Acids Res. 1999;27:4636–4641. [PMC free article] [PubMed] [Google Scholar]

10. De Mot R, Nagy I, Walz J, Baumeister W. Proteasomes and other self-compartmentalizing proteases in prokaryotes. Trends Microbiol. 1999;7:89–92. [PubMed] [Google Scholar]

11. Doern G V, Brueggemann A B, Huynh H, Wingert E. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997–98. Emerg Infect Dis. 1999;5:757–765. [PMC free article] [PubMed] [Google Scholar]

12. Ehrenshaft M, Bilski P, Li M Y, Chignell C F, Daub M E. A highly conserved sequence is a novel gene involved in de novo vitamin B6 biosynthesis. Proc Natl Acad Sci USA. 1999;96:374–378. [PMC free article] [PubMed] [Google Scholar]

13. Ewing B, Hillier L, Wendl M, Green P. Base-calling of automated sequencer traces using Phred. I. Accuracy assessment. Genome Res. 1998;8:175–185. [PubMed] [Google Scholar]

14. Fischer W. Physiology of lipoteichoic acids in bacteria. In: Rose A H, Tempest D W, editors. Advances in microbial physiology. Vol. 29. London, England: Academic Press; 1988. pp. 233–296. [PubMed] [Google Scholar]

15. Garcia P, Martin A C, Lopez R. Bacteriophages of Streptococcus pneumoniae: a molecular approach. In: Tomasz A, editor. Streptococcus pneumoniae: molecular biology and mechanisms of disease. Larchmont, N.Y: Mary Ann Liebert, Inc.; 2000. pp. 211–222. [Google Scholar]

16. Gasc A M, Giammarinaro P, Richter S, Sicard M. Organization around the dnaA gene of Streptococcus pneumoniae. Microbiology. 1998;144:433–439. [PubMed] [Google Scholar]

17. Gordon D, Abajian C, Green P. Consed: a graphical tool for sequence finishing. Genome Res. 1998;8:195–202. [PubMed] [Google Scholar]

18. Heiner C R, Hunkapiller K L, Chen S M, Glass J I, Chen E Y. Sequencing multimegabase-template DNA with BigDye terminator chemistry. Genome Res. 1998;8:557–561. [PMC free article] [PubMed] [Google Scholar]

19. Henikoff S, Henikoff J G, Pietrokovski S. Blocks+: a non-redundant database of protein alignment blocks derived from multiple compilations. Bioinformatics. 1999;15:471–479. [PubMed] [Google Scholar]

20. Hofmann K, Bucher P, Falquet L, Bairoch A. The PROSITE database, its status in 1999. Nucleic Acids Res. 1999;27:215–219. [PMC free article] [PubMed] [Google Scholar]

21. Iannelli F, Pearce B J, Pozzi G. The type 2 capsule locus of Streptococcus pneumoniae. J Bacteriol. 1999;181:2652–2654. [PMC free article] [PubMed] [Google Scholar]

22. Klein D L. Pneumococcal disease and the role of conjugate vaccines. Microb Drug Resist. 1999;5:147–157. [PubMed] [Google Scholar]

23. Lee M S, Morrison D A. Identification of a new regulator in Streptococcus pneumoniae linking quorum sensing to competence for genetic transformation. J Bacteriol. 1999;181:5004–5016. [PMC free article] [PubMed] [Google Scholar]

24. Lowe T M, Eddy S R. tRNAscan-SE: a program for improved detection of transfer RNA genes in genomic sequence. Nucleic Acids Res. 1997;25:955–964. [PMC free article] [PubMed] [Google Scholar]

25. Maidak B L, Cole J R, Parker C T, Jr, Garrity G M, Larsen N, Li B, Lilburn T G, McCaughey M J, Olsen G J, Overbeek R, Pramanik S, Schmidt T M, Tiedje J M, Woese C R. A new version of the RDP (Ribosomal Database Project) Nucleic Acids Res. 1999;27:171–173. [PMC free article] [PubMed] [Google Scholar]

26. Marciset O, Jeronimus-Stratingh M C, Mollet B, Poolman B. Thermophilin 13, a nontypical antilisterial poration complex bacteriocin, that functions without a receptor. J Biol Chem. 1997;272:14277–14282. [PubMed] [Google Scholar]

27. Martin B, Humbert O, Camara M, Guenzi E, Walker J, Mitchell T, Andrew P, Prudhomme M, Alloing G, Hakenbeck R, et al. A highly conserved repeated DNA element located in the chromosome of Streptococcus pneumoniae. Nucleic Acids Res. 1992;20:3479–3483. [PMC free article] [PubMed] [Google Scholar]

28. Massire C, Jaeger L, Westhof E. Derivation of the three-dimensional architecture of bacterial ribonuclease P RNAs from comparative sequence analysis. J Mol Biol. 1998;279:773–793. [PubMed] [Google Scholar]

29. Mazmanian S K, Liu G, Ton-That H, Schneewind O. Staphylococcus aureus sortase, an enzyme that anchors surface proteins to the cell wall. Science. 1999;285:760–763. [PubMed] [Google Scholar]

30. Mitchell T J. Virulence factors and the pathogenesis of disease caused by Streptococcus pneumoniae. Res Microbiol. 2000;151:413–419. [PubMed] [Google Scholar]

31. Morona J K, Guidolin A, Morona R, Hansman D, Paton J C. Isolation, characterization, and nucleotide sequence of IS_1202_, an insertion sequence of Streptococcus pneumoniae. J Bacteriol. 1994;176:4437–4443. [PMC free article] [PubMed] [Google Scholar]

32. Oggioni M R, Claverys J P. Repeated extragenic sequences in prokaryotic genomes: a proposal for the origin and dynamics of the RUP element in Streptococcus pneumoniae. Microbiology. 1999;145:2647–2653. [PubMed] [Google Scholar]

33. Overweg K, Kerr A, Sluijter M, Jackson M H, Mitchell T J, de Jong A P, de Groot R, Hermans P W. The putative proteinase maturation protein A of Streptococcus pneumoniae is a conserved surface protein with potential to elicit protective immune responses. Infect Immun. 2000;68:4180–4188. [PMC free article] [PubMed] [Google Scholar]

34. Pallen M J, Lam A C, Antonio M, Dunbar K. An embarrassment of sortases—a richness of substrates? Trends Microbiol. 2001;9:97–101. [PubMed] [Google Scholar]

35. Pericone C D, Overweg K, Hermans P W, Weiser J N. Inhibitory and bactericidal effects of hydrogen peroxide production by Streptococcus pneumoniae on other inhabitants of the upper respiratory tract. Infect Immun. 2000;68:3990–3997. [PMC free article] [PubMed] [Google Scholar]

36. Peterson S, Cline R T, Tettelin H, Sharov V, Morrison D A. Gene expression analysis of the Streptococcus pneumoniae competence regulons by use of DNA microarrays. J Bacteriol. 2000;182:6192–6202. [PMC free article] [PubMed] [Google Scholar]

37. Poland G A. The burden of pneumococcal disease: the role of conjugate vaccines. Vaccine. 1999;17:1674–1679. [PubMed] [Google Scholar]

38. Poolman B. Energy transduction in lactic acid bacteria. FEMS Microbiol Rev. 1993;12:125–148. [PubMed] [Google Scholar]

39. Reichmann P, Hakenbeck R. Allelic variation in a peptide-inducible two-component system of Streptococcus pneumoniae. FEMS Microbiol Lett. 2000;190:231–236. [PubMed] [Google Scholar]

40. Rimini R, Birger J, Feeger G, Roberts T, de Francesco M, Gozzi A, Faggioni F, Domenici E, Wallace D, Frandssen N, Polissi A. Global analysis of transcription kinetics during competence development in Streptococcus pneumoniae using high density DNA arrays. Mol Microbiol. 2000;36:1279–1292. [PubMed] [Google Scholar]

41. Schneewind O, Mihaylova-Petkov D, Model P. Cell wall sorting signals in surface proteins of gram-positive bacteria. EMBO J. 1993;12:4803–4811. [PMC free article] [PubMed] [Google Scholar]

42. Sicard A M. A new synthetic medium for Diplococcus pneumoniae and its use for the study of reciprocal transformations at the amiA locus. Genetics. 1964;50:31–44. [PMC free article] [PubMed] [Google Scholar]

43. Smith T F, Waterman M S. Identification of common molecular subsequences. J Mol Biol. 1981;147:195–197. [PubMed] [Google Scholar]

44. Steiner K, Malke H. Primary structure requirements for in vivo activity and bidirectional function of the transcription terminator shared by the oppositely oriented skc/rel-orf1 genes of Streptococcus equisimilis H46A. Mol Gen Genet. 1997;255:611–618. [PubMed] [Google Scholar]

45. Thornsberry C, Ogilvie P T, Holley H P, Jr, Sahm D F. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study. Antimicrob Agents Chemother. 1999;43:2612–2623. [PMC free article] [PubMed] [Google Scholar]

46. Throup J P, Koretke K K, Bryant A P, Ingraham K A, Chalker A F, Ge Y, Marra A, Wallis N G, Brown J R, Holmes D J, Rosenberg M, Burnham M K. A genomic analysis of two-component signal transduction in Streptococcus pneumoniae. Mol Microbiol. 2000;35:566–576. [PubMed] [Google Scholar]

47. Tomasz A. Streptococcus pneumoniae: molecular biology and mechanisms of disease. Larchmont, N.Y: Mary Ann Liebert, Inc.; 2000. p. 11. [Google Scholar]

48. Tu A-H T, Fulgham R L, McCrory M A, Briles D E, Szalai A J. Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun. 1999;67:4720–4724. [PMC free article] [PubMed] [Google Scholar]

49. Wani J H, Gilbert J V, Plaut A G, Weiser J N. Identification, cloning, and sequencing of the immunoglobulin A1 protease gene of Streptococcus pneumoniae. Infect Immun. 1996;64:3967–3974. [PMC free article] [PubMed] [Google Scholar]

50. Weiser J. Phase variation of Streptococcus pneumoniae. In: Fischetti V A, Novick R P, Ferretti J J, Portnoy D A, Rood J I, editors. Gram-positive pathogens. Washington, D.C.: ASM Press; 2000. pp. 225–231. [Google Scholar]

52. Zahner D, Hakenbeck R. The Streptococcus pneumoniae beta-galactosidase is a surface protein. J Bacteriol. 2000;182:5919–5921. [PMC free article] [PubMed] [Google Scholar]

53. Zwieb C, Samuelsson T. SRPDB (Signal Recognition Particle Database) Nucleic Acids Res. 2000;28:171–172. [PMC free article] [PubMed] [Google Scholar]


Articles from Journal of Bacteriology are provided here courtesy of American Society for Microbiology (ASM)